Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms

A gain-of-function mutation in Janus kinase 2 (JAK2V617F) is at the basis of the majority of chronic myeloproliferative neoplasms (MPN). Enhanced activation of other downstream pathways including the PI3K/mTOR pathway has been documented as well. In this study we evaluated the effects of JAK1/2 inhi...

Full description

Saved in:
Bibliographic Details
Main Author: Martinelli, Serena (auth)
Format: Electronic Book Chapter
Language:English
Published: Florence Firenze University Press 2017
Series:Premio Tesi di Dottorato 60
Subjects:
Online Access:OAPEN Library: download the publication
OAPEN Library: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 oapen_2024_20_500_12657_55390
005 20220531
003 oapen
006 m o d
007 cr|mn|---annan
008 20220531s2017 xx |||||o ||| 0|eng d
020 |a 978-88-6453-565-4 
020 |a 9788864535654 
020 |a 9788864535647 
020 |a 9788892731684 
040 |a oapen  |c oapen 
024 7 |a 10.36253/978-88-6453-565-4  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a MF  |2 bicssc 
072 7 |a MQP  |2 bicssc 
072 7 |a PS  |2 bicssc 
072 7 |a PSB  |2 bicssc 
072 7 |a PSD  |2 bicssc 
100 1 |a Martinelli, Serena  |4 auth 
245 1 0 |a Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms 
260 |a Florence  |b Firenze University Press  |c 2017 
300 |a 1 electronic resource (80 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Premio Tesi di Dottorato  |v 60 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a A gain-of-function mutation in Janus kinase 2 (JAK2V617F) is at the basis of the majority of chronic myeloproliferative neoplasms (MPN). Enhanced activation of other downstream pathways including the PI3K/mTOR pathway has been documented as well. In this study we evaluated the effects of JAK1/2 inhibitors, alone and in combination with mTOR, with a dual mTOR/PI3K inhibitor and with a pan PI3K inhibitor in in-vitro and in-vivo MPN models. Our findings of strong synergy between the JAK2 inhibitors and mTOR/PI3K inhibitor suggested that we might be able to administer these drugs at lower concentrations than when the drugs are used individually. This provides a framework for combination trials using compounds in patients with myeloproliferative neoplasms 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Pre-clinical medicine: basic sciences  |2 bicssc 
650 7 |a Pharmacy / dispensing  |2 bicssc 
650 7 |a Biology, life sciences  |2 bicssc 
650 7 |a Biochemistry  |2 bicssc 
650 7 |a Molecular biology  |2 bicssc 
856 4 0 |a www.oapen.org  |u https://library.oapen.org/bitstream/id/269b6ed9-6e4c-4f34-9ca4-c159499be23f/9788864535654.pdf  |7 0  |z OAPEN Library: download the publication 
856 4 0 |a www.oapen.org  |u https://library.oapen.org/handle/20.500.12657/55390  |7 0  |z OAPEN Library: description of the publication